Vaxart reports FY2024 net loss $66.9M, revenue $28.7M; initiates Phase 1 norovirus trial

Vaxart, Inc.

Net loss $66.9M ($0.33/sh) vs $82.5M in 2023; revenue $28.7M (up from $7.4M).
Cash $51.7M provides runway into Q4 2025; workforce reduced ~10% after COVID trial stop-work order.
Phase 1 trial of second-gen norovirus vaccine started; topline data expected mid-2025.
COVID-19 Phase 2b sentinel cohort enrolled; U.S. government stop-work order issued, only per-protocol follow-up allowed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.